1. Home
  2. VYGR vs IDAC Comparison

VYGR vs IDAC Comparison

Compare VYGR & IDAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Voyager Therapeutics Inc.

VYGR

Voyager Therapeutics Inc.

N/A

Current Price

$2.45

Market Cap

193.5M

Sector

Health Care

ML Signal

N/A

IDAC

Iron Dome Acquisition I Corp. Class A Ordinary Shares

N/A

Current Price

$10.00

Market Cap

216.7M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
VYGR
IDAC
Founded
2013
2025
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
193.5M
216.7M
IPO Year
2015
2026

Fundamental Metrics

Financial Performance
Metric
VYGR
IDAC
Price
$2.45
$10.00
Analyst Decision
Strong Buy
Analyst Count
11
0
Target Price
★ $14.89
N/A
AVG Volume (30 Days)
★ 584.2K
81.9K
Earning Date
11-09-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $10,135,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$129.75
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.33
$9.90
52 Week High
$5.55
$10.05

Technical Indicators

Market Signals
Indicator
VYGR
IDAC
Relative Strength Index (RSI) 27.89 53.76
Support Level N/A $9.96
Resistance Level $3.30 $10.00
Average True Range (ATR) 0.13 0.01
MACD -0.03 -0.00
Stochastic Oscillator 12.57 16.67

Price Performance

Historical Comparison
VYGR
IDAC

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.

About IDAC Iron Dome Acquisition I Corp. Class A Ordinary Shares

Iron Dome Acquisition I Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

Share on Social Networks: